Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (546)	6/23/2003 2:48:27 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 1022

Thanks for the post. >>My gut says that the MEDX antibody is better because it binds a conformational epitope while J591 binds a linear epitope (a long science discussion)<< Gut? His "gut" can be found at slide #25, medx's presentation at the GS conf. BTW, there have actually been some objective responses, even at least one CR, using gp100 in metastatic melanoma using novel adjuvants like il-2 and/or gc-sf (I'm sure I've got the abbr. wrong on that one).

To: Icebrg who wrote (546)	6/23/2003 8:15:49 PM
From: Madharry	Read Replies (1) \| Respond to of 1022

I own these 3 too. Who is Dr. Garren? Is he any good at this?

To: Icebrg who wrote (546)	6/26/2003 10:40:11 AM
From: Icebrg	Read Replies (2) \| Respond to of 1022

Anti-CD20 There seems to be a strong interest to develop a Rituximab Mk II. Just the other day Genentech and Idec said that they had agreed to do so. DNA/IDPH Genentech and IDEC Announce Humanized Anti-CD20 Antibody Development Collaboration Friday June 20, 4:19 pm ET SOUTH SAN FRANCISCO, Calif. and SAN DIEGO--(BUSINESS WIRE)--June 20, 2003--Genentech, Inc. (NYSE:DNA - News) and IDEC Pharmaceuticals Corporation (Nasdaq:IDPH - News) today announced plans to develop one or more new humanized anti-CD20 antibodies targeting B-cell disorders for a broad range of indications. Financial terms of the profit-sharing collaboration were not disclosed. Genentech and IDEC plan to file an investigational new drug application (IND) on their first humanized anti-CD20 antibody by the end of this year. The companies plan to work efficiently together to develop and commercialize additional anti-CD20 products that are targeted for specific patient populations, depending on the severity of their B-cell disorder. The primary focus of this collaboration will be to develop and launch a humanized anti-CD20 molecule while evaluating the utility for more efficacious follow-on humanized molecules. After that it turned out that it is now Biogen who is Genentech's partner, but I guess they don't mind as long as they can get the mAb out of the door. AMEV In the beginning of this year, AMEV announced that their thinking was more or less the same. Applied Molecular Evolution Advances Optimized Versions of anti-TNF alpha and anti-CD20 Monoclonal Antibody Therapeutic Candidates ame.biz MEDX And today we had the announcement from Genmab, who wants to try to develop a fully human version. GENMAB’S HUMAX-CD20 CANCER ANTIBODY SHOWS PROMISING RESULTS IN PRIMATE STUDY HuMax-CD20 depleted B-cells, the target in non-Hodgkins lymphoma, for longer than rituximab Message 19062685 No doubt there may very well be other candidates under development which I have not noticed. From a fully human standpoint isn't it somewhat surprising that DNA/Idec went with a humanized version. (Rituxan is as far as I know only chimeric - which is even more surprising). Erik